Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 12/20 | 0.44 |
| ▸ | DHODH | Q02127 | 2/20 | 0.42 |
| ▸ | FLT1 | P17948 | 2/20 | 0.40 |
| ▸ | FLT4 | P35916 | 2/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1206949 | 0.88 | FLT1 (0.45) | SCN9ADHODHFLT1FLT4KDR | |
| SCHEMBL1207414 | 0.84 | MAPK10 (0.44) | SCN9ADHODHMAPK8MAPK10 | |
| SCHEMBL1207419 | 0.81 | FLT1 (0.58) | FLT1FLT4KDR | |
| SCHEMBL1205853 | 0.80 | FLT1 (0.44) | SCN9AFLT1FLT4KDR | |
| SCHEMBL1207542 | 0.78 | FLT1 (0.49) | SCN9ADHODHFLT1FLT4KDR | |
| SCHEMBL1207547 | 0.75 | FLT1 (0.59) | SCN9AFLT1FLT4KDR | |
| SCHEMBL4374657 | 0.73 | BCL2L1 (0.52) | FLT1FLT4KDRMAPK8MAPK10 | |
| SCHEMBL4375641 | 0.72 | FLT1 (0.51) | SCN9AFLT1FLT4KDR | |
| SCHEMBL1206952 | 0.72 | DHODH (0.40) | SCN9ADHODHMAPK8MAPK10DRD2 | |
| SCHEMBL4375633 | 0.71 | PTGS2 (0.53) | SCN9AFLT1FLT4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879884-B2 | 6-(2-Chloro-phenyl)-5-methyl-pyridine-3-sulfonic acid 2-chloro-4-fluoro-benzoylamide; potassium salt, used as antiproliferative, anticarcinogenic or antitumor agents | HOFFMANN-LA ROCHE INC. (US) | 2011-02-01 | — | — | US | claimed |
| US-20100256200-A1 | ARYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-07 | — | — | US | claimed |
| US-7879884-B2 | 6-(2-Chloro-phenyl)-5-methyl-pyridine-3-sulfonic acid 2-chloro-4-fluoro-benzoylamide; potassium salt, used as antiproliferative, anticarcinogenic or antitumor agents | HOFFMANN-LA ROCHE INC. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20100256200-A1 | ARYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-07 | — | — | US | disclosed |
| EP-2148861-A1 | ARYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. Hoffmann-Roche AG (CH) | 2010-02-03 | — | — | EP | disclosed |
| WO-2008138594-A1 | ARYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256200-A1 | ARYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | ARSA, STS, SULT2A1 | SCN9A 1628/4885DHODH 647/4885FLT1 2946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.